Perturbations of BRCA1 function can act as a potent driver of cancer progression and can impact therapeutic responses to chemotherapies including platinum drugs and PARP inhibitors (Farmer et al., 2005; Li and Greenberg, 2012; Venkitaraman, 2014; Lord and Ashworth, 2016, 2017; Mylavarapu et al., 2018). This evidence concerns the gene PARP1 and cancer.